Skip to main content
SpringerLink
Log in
Book cover

PET/CT-Atlas pp 341–362Cite as

Lymphome

  • Chapter

  • 845 Accesses

Auszug

Aachener, Ulmer und Bonner Teams [1, 2, 4, 21, 25, 26] haben in Pilotstudien den PET-Status bereichert. Im Frankfurter Patientenkollektiv ragte dieses Krankengut zwischen 1994 und 1999 nicht vergleichbar heraus [35]. In Leipzig wurde die Systematik der PET-Anwendung bei Kindern und Jugendlichen mit Hodgkin-Erkrankung bei einem großen Untersuchungsgut evaluiert [16]. PET hat hier SPECT-Tracern [15] den Rang abgelaufen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Academy of Molecular Imaging (2005) Molecular Imaging and Biology (Scientific Abstracts of the 2005 Annual Conference of the Academy of Molecular Imaging, Orlando, Florida). Springer, Heidelberg, pp 79–180

    Google Scholar 

  2. Bangerter M, Kotzerke J, Grieshammer M et al. (1999) Positron emission tomography with 18 F-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 38:799–804

    Article  PubMed  CAS  Google Scholar 

  3. Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff B, Goldenberg DM, Hör G (1994) Initial clinical results with Tc-99 m labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 73:896–899

    Article  PubMed  CAS  Google Scholar 

  4. Cremerius U, Fabry U, Neuerburg J et al. Positron emission tomography with FDG detect residual disease after therapy of malignant lymphoma Nucl Med Comm 19:1055–1063

    Google Scholar 

  5. Deutsche Gesellschaft für Nuklearmedizin (2004) Empfehlungen der Strahlenschutzkommission (Anwendung der Positronenemissionstomographie (PET) als effizientes dosissparendes Diagnoseverfahren). Nuklearmedizin PET 3:N35–N36

    Google Scholar 

  6. DeVita VT, Canellos GP (1999) The lymphomas. Semin Hematol 36:84–94

    PubMed  CAS  Google Scholar 

  7. Eary JF et al (1990) Imaging and Treatment of B-cell lymphoma. J Nucl Med 31:1257–68

    PubMed  CAS  Google Scholar 

  8. Elstrom R, Guan L, Baker G, et al. (2003) Utility of FDG PET scanning in lymphoma by WHO classification. Blood 101:3875–6

    Article  PubMed  CAS  Google Scholar 

  9. Freudenberg LS, Antoch G, Schütt P et al. (2004) FDG-PET/ CT in restaging of patients with lymphoma. Eur J Nucl Med Molec Imaging 31:325–9

    Article  CAS  Google Scholar 

  10. Gambhir SS, Czernin J, Schwimmer J et al. (2001) A tabulated summary of the FDG PET literature. J Nucl Med (Suppl) 42:1–93

    Google Scholar 

  11. Hahn K, Pfluger Th (2004) Has PET become an important clinical tool in pediatric imaging? Eur J Nucl Med 31:615–621

    Article  Google Scholar 

  12. Herrmann S, Wormanns D, Pixberg M et al. (2005) Staging in childhood lymphoma (Differences between FDG-PET and CT). Nuklearmedizin 44:1–7

    Google Scholar 

  13. Hoskin PJ (2003) PET in lymphoma:what are the oncologists needs? Eur J Nucl Med 30(Suppl 1):37–41

    Article  Google Scholar 

  14. Juweid ME, Wiseman G, Mendal Y et al. (2004) Integrated positron emission tomography/computed tomography-based response classification for non-Hodgkin’s lymphoma (Abstr. 66). Mol Imaging Biology 6:86

    Google Scholar 

  15. Kapucu LÖ, Akyüz C, Vural G, Oguz A, Atasever T et al. (1997) Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99 m-Sestamibi. J Nucl Med 38:243–247

    PubMed  CAS  Google Scholar 

  16. Körholz D, Kluge R, Wickmann L et al. (2003) Importance of F-18 fluorodeoxy D-2 glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin’s lymphoma in childhood and adolescance-consequences for the GHPOH-HD 2003 protocol. Onkologie 26:489–493

    Article  PubMed  Google Scholar 

  17. Krausse A, Kluge R, Mauz-Koerholz C et al. (2004) Initial staging of Hodgkin’s disease (HD) in children by 18 F-FDG PET vs CT/MRI/US (Abstr.350). Eur J Nucl Med Mol Imaging Suppl 2 31:285–286

    Google Scholar 

  18. Leskinen-Kallo S, Ruotsalainen U, Nagren K, Teräs M, Joensuu H (1991) Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. J Nucl Med 32:1211–1218

    Google Scholar 

  19. Martiat Ph, Ferrant A, Labar D et al. (1988) In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin’s lymphoma using positron emission tomography. J Nucl Med 29:1633–1637

    PubMed  CAS  Google Scholar 

  20. McDounell PJ, Becker LC, Bulkley BH et al. (1981) Thallium imaging in cardiac lymphoma. Am Heart J 101:809–914

    Article  Google Scholar 

  21. Mijnhout GS, Hoekstra OS, van Lingen A et al. (2003) How morphometric analysis of metastatic loads predicts the (un)usefulnes of PET scanning: the case of lymphnode staging in melanoma. J Clin Pathol 56:283–286

    Article  PubMed  CAS  Google Scholar 

  22. Moog F, Kotzerke J, Reske SN et al (1999) FDG PET can replace bone szintigraphy in primary staging of malignant lymphoma. J Nucl Med 40:1487–13

    Google Scholar 

  23. Naumann R, Vaic A, Beuthien-Baumann B et al. (2004) Substantial impact of FDG PET imaging on the therapy decision in patients with early stage Hodgkin’s lymphoma. Br J Cancer 90:620–625

    Article  PubMed  CAS  Google Scholar 

  24. Okada J, Yoshikawa K, Imazeki K et al. (1991) The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 32:686–691

    PubMed  CAS  Google Scholar 

  25. Paul R (1987) Comparison of fluorine-18-2 fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 28:288–292

    PubMed  CAS  Google Scholar 

  26. Reske S, Kotzerke J (2001) FDG-PET for clinical use(Results of the 3rd German Interdisciplinary Consensus Conference, “Onko-PET III”, 21 July and 19 September 2000). Eur J Nucl Med 28:1707–1723

    Article  PubMed  CAS  Google Scholar 

  27. Ruhlmann J, Oehr P, Biersack HJ (1998) (Hrsg) PET in der Onkologie. Springer, Berlin 145–152

    Google Scholar 

  28. Schaefer NG, Hany ThF, Taverna Ch et al. (2004) Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging-Do we need contrast-enhanced CT? Radiology 231:publ. online

    Google Scholar 

  29. Spaepen K, Stroobants S, Dupont P et al. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose(18F-FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: Is PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419

    PubMed  CAS  Google Scholar 

  30. Spaepen K, Stroobants S, Dupont P et al. (2002) Early restaging positron emission tomography with 18 F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13:1356–63

    Article  PubMed  CAS  Google Scholar 

  31. Sun S, Kao Ch (2001) Negative results of 18 F-FDG and 67 Ga-citrate scintigraphy in gastric MALT lymphoma. Ann Nucl Med Sci 14:183–86

    Google Scholar 

  32. Tartar M, Kipper MS (2004) Positron emission tomography scan findings of autoimmun lymphoproliferative syndrome. Molecular Imaging and Biology 6:124–125

    Article  PubMed  Google Scholar 

  33. Tatsumi M, Kitayama H, Sugahara H et al. (2001) Wholebody hybrid PET with 18-FDG in the staging of non-Hodgkin’s lymphoma. J Nucl Med 42:601–608

    PubMed  CAS  Google Scholar 

  34. Voelker T, Denecke T, Amthauer H et al. (2004) The use of FDG PET for primary staging in pediatric Hodgkin’s lymphoma: comparison with conventional imaging modalities (Abstr. 275). Eur J Nucl Med Mol Imaging (Suppl) 2 31: S270

    Google Scholar 

  35. Walter WA Forget about RECIST: Towards molecular imaging based treatment planning (zit. b. [1] Abstr. 67) 218

    Google Scholar 

  36. Weidmann E, Baican B, Hertel A et al. (1999) Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leukemia and Lymphoma 34:545–551

    Google Scholar 

  37. Wirth A, Seymour JF, Hicks RJ et al. (2002) Fluorine F-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma. Am J Med 112:262–268

    Article  PubMed  Google Scholar 

  38. Yamane T, Daimaru O, Ito S et al. (2004) Decreased 18 F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphoma. J Nucl Med 45:1838–42

    PubMed  Google Scholar 

  39. Young CS, Young BL, Smith SM (1998) Staging Hodgkin disease with 18-FDG-PET comparsion with CT and surgery. Clin Pos Imaging 1:161–164

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

(2006). Lymphome. In: PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31215-3_9

Download citation

  • DOI: https://doi.org/10.1007/3-540-31215-3_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31214-7

  • Online ISBN: 978-3-540-31215-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation